Navigation Links
Siemens Receives EU Antitrust Clearance for Acquisition of Dade Behring
Date:10/25/2007

or words of similar meaning. Such statements are based on our current expectations and certain assumptions, and are, therefore, subject to certain risks and uncertainties. A variety of factors, many of which are beyond Siemens' control, affect its operations, performance, business strategy and results and could cause the actual results, performance or achievements of Siemens worldwide to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. For us, particular uncertainties arise, among others, from: changes in general economic and business conditions (including margin developments in major business areas); the challenges of integrating major acquisitions and implementing joint ventures and other significant portfolio measures; changes in currency exchange rates and interest rates; introduction of competing products or technologies by other companies; lack of acceptance of new products or services by customers targeted by Siemens worldwide; changes in business strategy; the outcome of pending investigations and legal proceedings; our analysis of the potential impact of such matters on our financial statements; as well as various other factors. More detailed information about our risk factors is contained in Siemens' filings with the SEC, which are available on the Siemens website, http://www.siemens.com, and on the SEC's website, http://www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the relevant forward-looking statement as expected, anticipated, intended, planned, believed, sought, estimated or projected. Siemens does not intend or assume any obligation to update or revise these forward-looking statements in light of developments which differ
'/>"/>
SOURCE Siemens Medical Solutions
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Siemens health services president calls IT benefits unassailable
2. Medical College receives $377K to study brain disease
3. Lucigen receives $750K grant to boost biofuel yields
4. Medical College receives $1.4M cancer grant
5. Wisconsin biotech firm receives $107K NIH grant
6. InvivoSciences receives NIH grant for heart technology
7. Medical College receives $11 million grant to study high blood pressure
8. Madison business receives $115,000 of new state biofuels funding
9. Superior receives funds for technical training
10. UWM receives state funding for plastics research
11. GEs Centricity EHR receives federal certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... variations, development of sequencing technologies, and their applications. ... well as companies developing them. Various applications of ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ) ... "Gene Therapy - Technologies, Markets and Companies" ... therapy are difficult to estimate as there is only ... in China since 2004. Gene ... estimates are based on epidemiology of diseases to be ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... 13 ,Exelixis, Inc. (Nasdaq: EXEL ) today announced ... common stock. The net proceeds of the,offering are approximately ... shares in the offering are being sold by,Exelixis. Exelixis ... up to an additional 1,050,000 shares of common stock. ...
... PITTSBURGH, Sept. 13 The Pittsburgh Life ... region,s life,sciences industry on a fast track ... and Chief Executive Officer, Renal Solutions, Inc., ... Initiatives, UPMC, John,L. Miclot, President and Chief ...
... September 13 In order,to meet its obligations under ... ("Shire") (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) is,publishing today ... June 2007,in accordance with International Financial Reporting Standards (IFRS). ... 2007, Shire announced its results in,respect of the same ...
Cached Biology Technology:The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors 2The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors 3IFRS Information - First Half of 2007 2IFRS Information - First Half of 2007 3IFRS Information - First Half of 2007 4IFRS Information - First Half of 2007 5IFRS Information - First Half of 2007 6IFRS Information - First Half of 2007 7IFRS Information - First Half of 2007 8IFRS Information - First Half of 2007 9IFRS Information - First Half of 2007 10IFRS Information - First Half of 2007 11IFRS Information - First Half of 2007 12IFRS Information - First Half of 2007 13IFRS Information - First Half of 2007 14IFRS Information - First Half of 2007 15IFRS Information - First Half of 2007 16IFRS Information - First Half of 2007 17IFRS Information - First Half of 2007 18IFRS Information - First Half of 2007 19IFRS Information - First Half of 2007 20IFRS Information - First Half of 2007 21IFRS Information - First Half of 2007 22IFRS Information - First Half of 2007 23IFRS Information - First Half of 2007 24IFRS Information - First Half of 2007 25IFRS Information - First Half of 2007 26IFRS Information - First Half of 2007 27IFRS Information - First Half of 2007 28IFRS Information - First Half of 2007 29IFRS Information - First Half of 2007 30IFRS Information - First Half of 2007 31IFRS Information - First Half of 2007 32IFRS Information - First Half of 2007 33
(Date:8/28/2015)... 2015 According to a new ... Assessment Type (Pen & Paper Based, Hosted, Biometrics), Service, ... Academic Research), Vertical and Region - Global Forecast to ... to grow from USD 2.4 Billion in 2015 to ... Growth Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/24/2015)...  Based on its recent analysis of the biometric products ... Biometrics Company of the Year Award. DERMALOG is the leading ... Africa . It has particularly gained prominence ... one of the largest biometric mass applications in the world, ... Bank of Nigeria with its biometric ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... down the biological trigger that gives rise to ... that can cause blindness and deafness. The findings ... lead to new treatments for osteoporosis and other ... Lawrence Livermore and Lawrence Berkeley national laboratories, the ...
... the common cold because there is scant evidence they ... the risks, according to a new systematic review of ... in the treatment of acute upper respiratory tract infections," ... the University of Auckland, New Zealand. "The implications for ...
... immunologists studying mast cells, known to play a central ... hormone-like molecule that can kill these cells by programming ... The findings move researchers another step closer to understanding ... researchers develop new treatments for allergy and inflammatory responses ...
Cached Biology News:Researchers track down cause of a disfiguring bone disorder 2Researchers track down cause of a disfiguring bone disorder 3Doctors should stop prescribing antibiotics for the common cold, review advises 2VCU study shows hormone-like molecule kills cells that cause inflammation in allergic disease 2
...
... antibody recognizes 30% of IgM-rheumatoid ... It does not cross-react with IgM, ... factor nor with pooled F(Ab)2 fragments. ... ELISA to detect rheumatoid factor. Product ...
... ,human IgG subclass 1 100% ,human IgG subclass ... 100% ,human IgG subclass 4 ... 100% ,human IgG Fc ... 0.04% ,human IgG Fab ...
...
Biology Products: